ALK and non-small cell lung carcinoma: However, based on these data and probably driven by the need for novel treatment options, regulatory authorities have approved atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for patients with metastatic NSCLC and EGFR/ALK alterations after failure of approved targeted therapy.